News - Cardio-vascular, Respiratory and Pulmonary

Filter

Popular Filters

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

06-02-2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

24-01-2014

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

Unigene and Tarix report highly increased oral bioavailability of "Peptelligence-engineered" TXA127

20-09-2012

USA-based Unigene Laboratories Laboratories (OTCBB: UGNE) and Tarix Pharmaceuticals yesterday announced…

Cardio-vascularLicensingPharmaceuticalResearchRespiratory and PulmonaryTarix PharmaceuticalsTXA127Unigene Labs

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

B-MS ties knot with Duke University on R&D

29-02-2012

Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

NICE publishes final technology appraisal guidance for four conditions

24-01-2012

The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy

22-11-2011

USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF

26-09-2011

US biotech firm InterMune (Nasdaq: ITMN) has reported that new data at the European Respiratory Society…

BiotechnologyCardio-vascularEsbrietHealthcareInterMunePharmaceuticalResearchRespiratory and Pulmonary

Novartis cancer drug imatinib shows efficacy in PAH

26-09-2011

Swiss drug major Novartis (NOVN: VX) yesterday announced new data today at the European Respiratory Society…

ActelionCardio-vascularImatinib MesylateNovartisPharmaceuticalResearchRespiratory and PulmonaryTracleer

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top